In our study, lung metastases derived from LM2-4luc (triple-negative breast cancer cells that secrete high levels of VEGF and IL-8), but not SN12luc (VHL-wild-type renal cancer cells that secrete low levels of VEGF and IL-8), responded to VT treatment. This evidence concerns the gene VEGFA and triple-negative breast carcinoma.